The mortality and economic burden of drug induced acute kidney injury are substantial, emphasizing the need for prevention and optimal treatment. Dr. Sandra Kane-Gill provides perspective on novel kidney biomarkers and how they offer a missing piece of the assessment for early detection and management of DI-AKI. Read the full manuscript at: https://accpjournals.onlinelibrary.wiley.com/doi/full/10.1002/phar.70071